Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043430 · ClinicalTrials.gov registry record · Phase 4
Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
A Phase 4 study, sponsored by Brooke Army Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03043430 is a Phase 4 study that was terminated before completion, run by Brooke Army Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT03043430, a Phase 4 study, was terminated before completion, sponsored by Brooke Army Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric patients requiring minor procedures in the Emergency Department setting. Patients will be randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam 0.3 mg/kg (M). The primary outcome will be change in anxiety using the Modified Yale Preoperative Anxiety Scale (mYPAS).
Interventions
- DRUG Ketamine 100 MG/ML
- DRUG Midazolam 5 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-05 |
| Est. Completion | 2023-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043430
The ClinicalTrials.gov registry entry for NCT03043430 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine 100 MG/ML is the first listed.
NCT03043430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043430 about?
NCT03043430 is a clinical study titled "Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients". Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric patients requiring minor procedures in the Emergency Department setting. Patients will be randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam 0.3 mg/kg (M). The primar...
What is the current status of trial NCT03043430?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2016-05. Estimated completion is 2023-04.
What interventions are being tested in trial NCT03043430?
The interventions under investigation include: Ketamine 100 MG/ML (DRUG), Midazolam 5 MG/ML (DRUG).
Who is sponsoring clinical trial NCT03043430?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.